179 related articles for article (PubMed ID: 24261748)
1. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
Norman P
Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
3. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
4. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
Norman P
Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.
Norman P
Expert Opin Ther Pat; 2012 Sep; 22(9):1105-9. PubMed ID: 22812580
[TBL] [Abstract][Full Text] [Related]
7. Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735.
Norman P
Expert Opin Ther Pat; 2012 Dec; 22(12):1479-83. PubMed ID: 22917158
[TBL] [Abstract][Full Text] [Related]
8. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
9. Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies.
Doma A; Kulkarni R; Palakodety R; Sastry GN; Sridhara J; Garlapati A
Bioorg Med Chem; 2014 Nov; 22(21):6209-19. PubMed ID: 25261929
[TBL] [Abstract][Full Text] [Related]
10. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
Labadie S; Barrett K; Blair WS; Chang C; Deshmukh G; Eigenbrot C; Gibbons P; Johnson A; Kenny JR; Kohli PB; Liimatta M; Lupardus PJ; Shia S; Steffek M; Ubhayakar S; van Abbema A; Zak M
Bioorg Med Chem Lett; 2013 Nov; 23(21):5923-30. PubMed ID: 24042009
[TBL] [Abstract][Full Text] [Related]
12. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
13. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
Shin H; Kim MK; Chong Y
Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
[TBL] [Abstract][Full Text] [Related]
16. Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.
Kim MK; Shin H; Cho SY; Chong Y
Bioorg Med Chem; 2014 Feb; 22(3):1156-62. PubMed ID: 24398382
[TBL] [Abstract][Full Text] [Related]
17. Comparative QSAR model generation using pyrazole derivatives for screening Janus kinase-1 inhibitors.
Sarithamol S; Pushpa VL; Divya V; Manoj KB
Chem Biol Drug Des; 2020 May; 95(5):503-519. PubMed ID: 32022397
[TBL] [Abstract][Full Text] [Related]
18. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
Kim H; Kim MK; Choo H; Chong Y
Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
Jasuja H; Chadha N; Kaur M; Silakari O
SAR QSAR Environ Res; 2014; 25(8):617-36. PubMed ID: 25148044
[TBL] [Abstract][Full Text] [Related]
20. Progress toward JAK1-selective inhibitors.
Menet CJ; Mammoliti O; López-Ramos M
Future Med Chem; 2015; 7(2):203-35. PubMed ID: 25686006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
